Loading...

PGEN PRECIGEN INC Investments/Divestments 8-K Filing

PRCG

PGN

PRECIGEN INC

(PGEN)

2023 8-K

Show Summary

Show Summary

Equity Offerings

Financial Statements

Financial Results

Nasdaq Compliance

Financial Results

Nasdaq Compliance Notice

Contract Termination

Management Change

Executive Compensation

Financial Results

Public Offering

Financial Condition

Annual Meeting Approval

Financial Results

Financial Results

Departure of Directors or C...

Financial Results

Financial Results and R&D U...

Annual Meeting of Stockholders

Financial Results

License Agreement with Alau...

Reaffirmation of Funding Es...

Financial Results

Public Offering

Financial Update

External Links:

Precigen, Inc. entered into an amended and restated exclusive license agreement with Alaunos Therapeutics for the research, development, and commercialization of T-cell receptor products for cancer treatment and prevention of HPV.

AI Assistant

PRECIGEN INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.